Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR for inoperable or locally recurrent thymoma
2010-019017-25Phase 2Completed
- Sponsor
- University of Regensburg
- Start
- Nov 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in thymoma, sponsored by University of Regensburg. Primary endpoint: Tumor shrinkage. Started Nov 2010; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
thymoma
Beyond the preview
Go deeper on 2010-019017-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019017-25.